{"meta":{"query_hash":"4338ff23aa9b","filters":{"venue":"Clinical Pharmacology Advances and Applications"},"cohort_total":4,"direct_labels_cover":0,"predictions_cover":4,"exported":4,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/4338ff23aa9b","api":"https://metacan.xera.ac/api/v1/cohort?venue=Clinical+Pharmacology+Advances+and+Applications"},"results":[{"id":"W2075428150","doi":"10.2147/cpaa.s64131","title":"Lack of effect of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug–drug interaction study","year":2014,"lang":"en","type":"article","venue":"Clinical Pharmacology Advances and Applications","topic":"Ion Transport and Channel Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Valeant Pharmaceuticals International","keywords":"Digoxin; Pharmacokinetics; Pharmacology; Therapeutic index; Medicine; Active metabolite; Tolerability; Chemistry; Metabolite; Oral administration; Urine; Drug; Endocrinology; Internal medicine; Adverse effect; Heart failure","score_opus":0.039659122879576195,"score_gpt":0.42283517403519394,"score_spread":0.38317605115561776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075428150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99922085,0.00025562392,0.00011032279,0.000020408715,0.0000039692404,0.000040610114,0.00007408558,0.0000048852808,0.00026928086],"genre_scores_gemma":[0.9991109,0.000118730524,0.00017386737,0.00006217662,0.000010260136,0.000017570685,0.00011972452,0.00000277954,0.00038396518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915636,0.0003265875,0.000069917645,0.0001773664,0.00019648272,0.00007329367],"domain_scores_gemma":[0.9992225,0.00022251831,0.00019959809,0.00007219628,0.000071560156,0.00021148796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016667133,0.0003798032,0.0009765262,0.00023206692,0.0003098625,0.00038438223,0.00020936842,0.00044096657,0.002061153],"category_scores_gemma":[0.0010972887,0.00022041168,0.00068380695,0.00020047092,0.00031550787,0.00038999086,0.00024025659,0.00047511846,0.00037632743],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32937902,0.02377898,0.33603352,0.0005347679,0.005288142,0.0017157102,0.0012315313,0.00069671153,0.19425438,0.00018434155,0.00085776875,0.10604517],"study_design_scores_gemma":[0.007002336,0.21964931,0.7501586,0.000018236396,0.0027340266,0.0017503895,0.0002559579,0.0014387199,0.013870361,0.00008438168,0.0029863883,0.000051298815],"about_ca_topic_score_codex":0.0011823468,"about_ca_topic_score_gemma":0.0022856754,"teacher_disagreement_score":0.002061153,"about_ca_system_score_codex":0.00038989345,"about_ca_system_score_gemma":0.0003502851,"threshold_uncertainty_score":0.008814514},"labels":[],"label_agreement":null},{"id":"W2507259647","doi":"10.2147/cpaa.s105165","title":"Systematic review and network meta-analysis of stroke-prevention treatments in patients with atrial fibrillation","year":2016,"lang":"en","type":"article","venue":"Clinical Pharmacology Advances and Applications","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics; Cancer Care Ontario; University of Toronto; St. Michael's Hospital; Toronto Public Health","funders":"University of Toronto; Government of Ontario","keywords":"Medicine; Edoxaban; Apixaban; Dabigatran; Warfarin; Rivaroxaban; Atrial fibrillation; Stroke (engine); Aspirin; Internal medicine; Hazard ratio; Clopidogrel; Randomized controlled trial; Anesthesia; Cardiology; Confidence interval","score_opus":0.09936278694505525,"score_gpt":0.45675288756865956,"score_spread":0.3573901006236043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2507259647","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0044165873,0.9927004,0.0009089202,0.00037336655,0.0002056287,0.00030046125,0.0007026944,0.000025423727,0.00036655375],"genre_scores_gemma":[0.2570266,0.7326053,0.0050514746,0.0012137454,0.0005566564,0.0017516632,0.0014577085,0.00003687021,0.0003000271],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9659231,0.023569189,0.0054691928,0.0021890858,0.0024008804,0.00044864207],"domain_scores_gemma":[0.953124,0.037517697,0.005508774,0.0013391473,0.00219377,0.00031662296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025075544,0.0026761247,0.017025061,0.008319471,0.00064089673,0.0029476199,0.0019798337,0.0019135808,0.003894908],"category_scores_gemma":[0.0672251,0.0012893134,0.03440659,0.008148218,0.00074903236,0.0018284539,0.0013886814,0.0020197288,0.00027123117],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011284786,0.000026328913,0.005253922,0.19021761,0.7914024,0.00008528706,0.00005172344,0.0011005481,0.00007691036,0.0002010785,0.0008266904,0.009628991],"study_design_scores_gemma":[0.0006608515,0.00015362789,0.0038548582,0.019087428,0.9736293,0.00009628643,0.000023891958,0.00047134503,0.00005480117,0.00050801405,0.0014390766,0.000020604151],"about_ca_topic_score_codex":0.007205379,"about_ca_topic_score_gemma":0.0137410285,"teacher_disagreement_score":0.025075544,"about_ca_system_score_codex":0.0025822548,"about_ca_system_score_gemma":0.0040969593,"threshold_uncertainty_score":0.13261372},"labels":[],"label_agreement":null},{"id":"W4200179740","doi":"10.2147/cpaa.s288842","title":"Pharmacological Profile of Viltolarsen for the Treatment of Duchenne Muscular Dystrophy: A Japanese Experience","year":2021,"lang":"en","type":"review","venue":"Clinical Pharmacology Advances and Applications","topic":"Muscle Physiology and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Muscular Dystrophy Canada; Alberta Innovates; Alberta Innovates - Health Solutions; Women and Children's Health Research Institute; Children's Health Research Institute","keywords":"Duchenne muscular dystrophy; Exon skipping; Dystrophin; Medicine; Muscular dystrophy; Muscle disorder; Clinical trial; Exon; Bioinformatics; Internal medicine; Genetics; Gene; Biology","score_opus":0.0735950491683823,"score_gpt":0.4762422176833558,"score_spread":0.4026471685149735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200179740","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12174233,0.8661008,0.0019353091,0.0014325395,0.00055722956,0.00014676689,0.00018044219,0.000043734235,0.007860876],"genre_scores_gemma":[0.32096937,0.664282,0.0039227745,0.0031774112,0.0006670634,0.00015481928,0.0004487785,0.000036042024,0.0063416213],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99986136,0.000038562863,0.000029430337,0.00002135957,0.000034783665,0.000014452223],"domain_scores_gemma":[0.99987817,0.000029486571,0.000021239939,0.000005310319,0.000043492546,0.00002228622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006251441,0.00031198282,0.0006809644,0.00032871994,0.00024681978,0.00042592763,0.000244511,0.00033381142,0.0012682829],"category_scores_gemma":[0.00033948285,0.00008095474,0.00039867626,0.0003242216,0.0001965901,0.00043836114,0.000241844,0.00091823423,0.00034708003],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00483228,0.0018474826,0.0031891742,0.010904592,0.0007897875,0.0020296173,0.0008567042,0.0004650581,0.11069795,0.0020590895,0.010616756,0.8517115],"study_design_scores_gemma":[0.0047995485,0.063341,0.059504237,0.0038104434,0.0055707335,0.02073019,0.0011535713,0.0013753291,0.07940736,0.001719495,0.7583073,0.00028081978],"about_ca_topic_score_codex":0.00040035203,"about_ca_topic_score_gemma":0.0011684024,"teacher_disagreement_score":0.0012682829,"about_ca_system_score_codex":0.00019310671,"about_ca_system_score_gemma":0.00038500823,"threshold_uncertainty_score":0.004242897},"labels":[],"label_agreement":null},{"id":"W4410326796","doi":"10.2147/cpaa.s509476","title":"Predictive Analysis of Non-Cardiac Drug-Induced QTc Interval Prolongation: A Cross-Sectional Study","year":2025,"lang":"en","type":"article","venue":"Clinical Pharmacology Advances and Applications","topic":"Cardiac electrophysiology and arrhythmias","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"King Abdullah International Medical Research Center","keywords":"Prolongation; QT interval; Medicine; Cross-sectional study; Internal medicine; Drug; Cardiology; Interval (graph theory); Pharmacology; Mathematics; Pathology; Combinatorics","score_opus":0.022311847070751057,"score_gpt":0.4537111245587702,"score_spread":0.43139927748801915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410326796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99884063,0.00042611235,0.00013112191,0.000038185157,0.000008879648,0.000011969835,0.00023647795,0.0000017674629,0.00030481524],"genre_scores_gemma":[0.9995128,0.00012384297,0.00009806169,0.00002659135,0.00001277513,0.0000062241775,0.00017952679,9.180715e-7,0.00003928901],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991303,0.0002923493,0.0001392313,0.00019559536,0.00015757186,0.00008495113],"domain_scores_gemma":[0.99612254,0.0009805985,0.0019379343,0.00026686463,0.00035980385,0.00033217663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001463834,0.000203549,0.00026920848,0.00058213965,0.0002878477,0.0005189464,0.0003298485,0.00032822796,0.0013817904],"category_scores_gemma":[0.0048044464,0.00023212288,0.00037988456,0.0007604343,0.00019390802,0.0004436993,0.00031643632,0.00050116953,0.00018193085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000141398405,0.000012532869,0.999637,0.0000046320474,0.0000140787515,0.000023303497,0.000014730687,0.000005806323,0.000024613892,0.0000039419497,0.000011958787,0.00023328347],"study_design_scores_gemma":[0.0000021284511,0.00007896342,0.9992372,0.0000059471254,0.000021665068,0.0003224432,0.00009727276,0.00011448117,0.000026162961,0.000007501585,0.0000848513,0.0000014394433],"about_ca_topic_score_codex":0.001615992,"about_ca_topic_score_gemma":0.0020431732,"teacher_disagreement_score":0.001615992,"about_ca_system_score_codex":0.00018410712,"about_ca_system_score_gemma":0.00030149464,"threshold_uncertainty_score":0.0077415705},"labels":[],"label_agreement":null}]}